INDOCO.BO
Indoco Remedies Limited
BSEINREQUITY
Healthcare
DELAYED
Last price
225.75
▲ 4.20 (1.90%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
222.40
Prev close
221.55
Day high
229.80
Day low
221.15
Volume
4.48K
Market cap
$20.74B
P/E (TTM)
—
52W range
190.00 – 348.10
Day trading desk
Gap from prior close
—
—
VWAP
224.32
+0.64% from price
Relative volume
1.95×
Unusually busy
Session range
3.91%
221.15 – 229.80
Position in range
53%
Mid range
ATR (14D)
—
Daily true range
Prior day high
—
PDH
Prior day low
—
PDL
Bid / ask spread
—
Quote not published
Session volume
4.28K
Avg 2.19K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on INDOCO.BO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
56.84M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Dec 26, 25 | Kare (Aruna Suresh) Promoter |
SELL | 5.53M | $122.87K | Direct |
| Dec 26, 25 | Kare Family Pvt. Trust Promoter |
BUY | 5.53M | $122.87K | Direct |
| Nov 25, 25 | Kare (Aruna Suresh) Promoter |
BUY | 5.53M | $123.98K | Direct |
| Nov 25, 25 | Kare (Aruna Suresh) Promoter |
SELL | 4.79M | $107.40K | Direct |
| Nov 25, 25 | Kare (Mdhura Suresh) Promoter |
SELL | 2.77M | $61.99K | Direct |
| Nov 25, 25 | Kare (Suresh G) Promoter |
SELL | 2.77M | $61.99K | Direct |
| Nov 25, 25 | Kare Family Pvt. Trust Promoter |
BUY | 7.56M | $169.39K | Direct |
| Nov 25, 25 | Panandikar (Aditi Milind) Promoter |
SELL | 2.77M | $61.99K | Direct |
| Aug 8, 25 | Kare (Mdhura Suresh) Promoter |
BUY | 7.30K | $24.96K | Direct |
| Aug 7, 25 | Panandikar (Aditi Milind) Promoter |
BUY | 20.80K | $70.04K | Direct |
| Aug 7, 25 | Panandikar (Mahika Milind) Promoter |
SELL | 7.80K | $25.44K | Direct |
| Aug 7, 25 | Panandikar (Megh Milind) Promoter |
SELL | 13.00K | $43.43K | Direct |
| Aug 7, 25 | Ramani (Rohan Anup) Promoter |
SELL | 7.30K | $23.94K | Direct |
| Mar 19, 25 | Shanteri Investment Pvt Ltd Promoter |
BUY | 12.15K | $32.32K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Bambolkar (Sundeep V.) |
UNREPORTED | 469.00K | Acquisition |
Kare (Aruna Suresh) |
Promoter | 0 | Sale |
Kare (Mdhura Suresh) |
Promoter | 2.48M | Sale |
Kare (Suresh G) |
Promoter | 1.29M | Sale |
Kare Family Pvt. Trust |
Promoter | 13.10M | Purchase |
Panandikar (Aditi Milind) |
Promoter | 2.92M | Sale |
Panandikar (Mahika Milind) |
Promoter | 0 | Sale |
Panandikar (Megh Milind) |
Promoter | 0 | Sale |
Ramani (Rohan Anup) |
Promoter | 0 | Sale |
Shanteri Investment Pvt Ltd |
Promoter | 15.86M | Acquisition |
Fundamentals
Market cap$20.74B
Enterprise value$30.66B
Revenue (TTM)$17.60B
Gross profit$11.96B
EBITDA$984.55M
Net income$-1.14B
EPS (TTM)$-12.17
Free cash flow—
Total cash$193.20M
Total debt$9.99B
Book value / share$123.55
Shares outstanding92.16M
Float36.37M
Short % of float—
Dividend yield0.09%
Beta (5Y)0.34
Valuation & profitability ratios
Trailing P/E—
Forward P/E36.59
PEG ratio—
Price / sales—
Price / book1.82
EV / revenue1.74
EV / EBITDA31.14
Gross margin67.95%
Operating margin-0.11%
Profit margin-6.47%
Return on equity—
Return on assets—
Debt / equity102.50
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $17.93B | $16.41B | $17.88B | $16.40B | — | +9.2% |
| Operating revenue | $17.93B | $16.41B | $17.88B | $16.40B | — | +9.2% |
| Cost of revenue | $5.42B | $4.98B | $5.82B | $5.39B | — | +8.7% |
| Gross profit | $12.51B | $11.43B | $12.06B | $11.01B | — | +9.5% |
| Research & development | $795.40M | $760.10M | $971.57M | $809.70M | — | +4.6% |
| Selling, general & admin | — | $2.60B | $2.12B | $1.67B | $1.37B | — |
| Total operating expense | $12.36B | $11.58B | $10.63B | $9.03B | — | +6.8% |
| Operating income | $153.50M | -$145.80M | $1.43B | $1.98B | — | +205.3% |
| Net interest income | -$1.22B | -$662.30M | -$350.50M | -$246.92M | — | -84.6% |
| Pre-tax income | -$1.07B | -$743.70M | $1.36B | $1.93B | — | -43.2% |
| Tax provision | -$78.10M | $35.80M | $387.95M | $505.41M | — | -318.2% |
| Net income | -$951.50M | -$737.40M | $984.60M | $1.42B | — | -29.0% |
| Net income to common | -$951.50M | -$737.40M | $984.60M | $1.42B | — | -29.0% |
| EBIT | $157.40M | -$81.40M | $1.71B | $2.17B | — | +293.4% |
| EBITDA | $1.42B | $1.06B | $2.63B | $2.87B | — | +34.5% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $259.30M | $120.96M | $148.56M | $109.25M | — | +114.4% |
| Cash & short-term investments | $458.40M | $153.17M | $255.93M | $149.20M | — | +199.3% |
| Accounts receivable | $4.89B | $3.52B | $4.06B | $3.51B | — | +38.8% |
| Inventory | $4.05B | $4.19B | $3.53B | $3.26B | — | -3.4% |
| Total current assets | $11.93B | $10.01B | $9.55B | $8.14B | — | +19.2% |
| Property, plant & equipment | $10.82B | $12.13B | $9.79B | $7.06B | — | -10.8% |
| Goodwill & intangibles | $2.01B | $1.92B | $1.88B | $1.24B | — | +4.5% |
| Total assets | $25.93B | $24.30B | $21.45B | $16.58B | — | +6.7% |
| Total current liabilities | $10.53B | $8.08B | $6.12B | $4.25B | — | +30.3% |
| Current debt | $5.20B | $4.45B | $3.03B | $1.71B | — | +16.9% |
| Long-term debt | $5.16B | $5.33B | $3.52B | $1.44B | — | -3.2% |
| Total debt | $10.90B | $9.94B | $6.72B | $3.33B | — | +9.7% |
| Total liabilities | $16.61B | $14.12B | $10.34B | $6.30B | — | +17.7% |
| Retained earnings | — | $6.72B | $7.65B | $6.87B | $5.64B | — |
| Shareholder equity | $9.39B | $10.22B | $11.10B | $10.28B | — | -8.1% |
| Working capital | $1.41B | $1.93B | $3.42B | $3.89B | — | -27.2% |
| Net tangible assets | $7.38B | $8.30B | $9.22B | $9.04B | — | -11.0% |
| Shares issued | 92.30M | 92.25M | 92.18M | 92.15M | — | +0.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$85.90M | -$83.70M | $1.24B | $1.93B | -2.6% |
| Depreciation & amortisation | $1.07B | $982.50M | $918.65M | $706.06M | +8.8% |
| Stock-based compensation | $6.00M | $18.70M | $26.90M | $6.58M | -67.9% |
| Change in working capital | $609.20M | -$324.80M | -$884.74M | -$731.89M | +287.6% |
| Operating cash flow | $2.26B | $907.60M | $1.55B | $1.79B | +149.4% |
| Capital expenditure | -$1.25B | -$2.58B | -$4.26B | -$2.07B | +51.5% |
| Investing cash flow | -$873.80M | -$2.60B | -$4.33B | -$2.08B | +66.4% |
| Dividends paid | -$19.10M | -$139.00M | -$207.06M | -$207.21M | +86.3% |
| Financing cash flow | -$1.33B | $1.69B | $1.22B | $228.04M | -178.9% |
| Free cash flow | $1.01B | -$1.68B | -$2.71B | -$284.23M | +160.2% |
| End cash position | $129.40M | $70.60M | $148.56M | $109.25M | +83.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.66B | $4.56B | $4.34B | $4.72B | $4.31B | +2.3% |
| Operating revenue | $4.66B | $4.56B | $4.34B | $4.72B | $4.31B | +2.3% |
| Cost of revenue | $1.58B | $1.41B | $1.20B | $1.45B | $1.35B | +12.1% |
| Gross profit | $3.08B | $3.15B | $3.14B | $3.26B | $2.96B | -2.1% |
| Research & development | $185.40M | $177.60M | $183.10M | $218.10M | $216.60M | +4.4% |
| Total operating expense | $3.02B | $2.98B | $3.14B | $3.16B | $3.08B | +1.3% |
| Operating income | $64.90M | $172.20M | -$5.00M | $108.00M | -$121.70M | -62.3% |
| Net interest income | -$282.90M | -$459.20M | -$256.40M | -$245.60M | -$261.20M | +38.4% |
| Pre-tax income | $777.20M | -$250.00M | -$313.10M | -$135.30M | -$366.60M | +410.9% |
| Tax provision | $122.80M | -$13.20M | -$18.60M | -$43.20M | -$3.10M | +1,030.3% |
| Net income | $649.90M | -$216.40M | -$297.90M | -$79.30M | -$357.90M | +400.3% |
| Net income to common | $649.90M | -$216.40M | -$297.90M | -$79.30M | -$357.90M | +400.3% |
| EBIT | $1.06B | $209.20M | -$56.70M | $110.30M | -$105.40M | +406.7% |
| EBITDA | $1.41B | $534.10M | $263.40M | $432.80M | $191.60M | +163.1% |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $259.30M | $126.60M | $120.96M | +104.8% |
| Cash & short-term investments | $458.40M | $231.50M | $153.17M | +98.0% |
| Accounts receivable | $4.89B | $4.53B | $3.52B | +8.1% |
| Inventory | $4.05B | $4.25B | $4.19B | -4.6% |
| Total current assets | $11.93B | $10.81B | $10.01B | +10.4% |
| Property, plant & equipment | $10.82B | $11.30B | $12.13B | -4.3% |
| Goodwill & intangibles | $2.01B | $1.95B | $1.92B | +3.2% |
| Total assets | $25.93B | $25.08B | $24.30B | +3.4% |
| Total current liabilities | $10.53B | $9.85B | $8.08B | +6.9% |
| Current debt | $5.20B | $4.92B | $4.45B | +5.6% |
| Long-term debt | $5.16B | $4.46B | $5.33B | +15.8% |
| Total debt | $10.90B | $9.99B | $9.94B | +9.1% |
| Total liabilities | $16.61B | $15.34B | $14.12B | +8.3% |
| Retained earnings | — | — | $6.72B | — |
| Shareholder equity | $9.39B | $9.80B | $10.22B | -4.1% |
| Working capital | $1.41B | $962.60M | $1.93B | +46.3% |
| Net tangible assets | $7.38B | $7.85B | $8.30B | -6.0% |
| Shares issued | 92.30M | 92.25M | 92.25M | +0.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Sep 2025 | -3.00 | -0.95 | +68.2% |
| Mar 2025 | -3.60 | -4.48 | -24.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | -5.90 | 3 | $18.83B | +13.1% |
| Next year | 6.15 | 4 | $20.55B | +9.2% |
Analyst targets & ownership
Mean target$268.00
High target$325.00
Low target$222.00
Implied upside18.72%
Analyst count4
ConsensusHOLD
Strong buy / Buy1 / 0
Hold2
Sell / Strong sell1 / 0
Held by insiders61.05%
Held by institutions17.84%
Institutions holding12
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
—
Peak to trough
Max drawdown 5Y
—
Peak to trough
ATR 14
—
Average true range
Beta (reported)
0.34
5Y monthly, from filing
Dividends & splits
Forward rate$0.20 / yr
Forward yield0.09%
5-year avg yield0.42%
Payout ratio45.39%
Ex-dividend dateSep 4, 2025
Next pay date—
Last split7.5:1
Split dateMay 17, 2012
Headlines
FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?
Motley Fool · 5m ago
Vistra Is the Quietest Big Winner of the AI Power Boom. Here's Why.
Motley Fool · 6m ago
AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?
Insider Monkey · 6m ago
Uber faces fine of nearly $1B over automated driver suspensions
TechCrunch · 15m ago
This Company Has Raised Its Dividend for 72 Straight Years. Almost Nobody Talks About It.
Motley Fool · 17m ago
This Chinese Tech Giant Quietly Cut Its Buyback 80% to Fund AI
24/7 Wall St. · 27m ago
Look Back: Long before Party on the Patio, Mötley Crüe rocked Pocono Downs
The Times-Leader (Wilkes-Barre, Pa.) · 28m ago
Prediction: ExxonMobil Raises Its Dividend More Than Wall Street Expects
Motley Fool · 29m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.